Zharko Pharma

Executive Summary

Zharko Pharma, a San Diego-based biotechnology company founded in 2019, is dedicated to discovering and developing novel small molecule therapeutics for oncology and rare diseases. The company aims to address significant unmet medical needs through innovative drug discovery, leveraging its expertise in medicinal chemistry and target biology. Although still in an early stage with no disclosed pipeline or commercial products, Zharko Pharma's focus on small molecules offers advantages in oral bioavailability, tissue penetration, and manufacturing scalability. The biotech landscape for oncology and rare disease remains highly active, with increasing demand for targeted therapies that minimize side effects. However, the lack of publicly available information on specific programs, preclinical data, or funding raises uncertainty about the company's near-term trajectory. Zharko Pharma's success will depend on advancing its lead candidates through preclinical development and into clinical trials, as well as securing partnerships or financing to support these efforts. Given the early nature of the company and limited visibility, the risk profile is elevated, but the potential for addressing high-need areas warrants close monitoring.

Upcoming Catalysts (preview)

• 2027Lead optimization and IND-enabling studies for lead candidate20% success
• TBDDisclosure of therapeutic target or pipeline details50% success
• 2026Series A or seed funding announcement40% success